Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis
Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis have?
Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis has 111 citations in the OpenAlex counts ScholarIQ stores.
When was Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis published?
Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis has 2019 year in the ScholarIQ index.
What is the open-access status of Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis?
Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis has hybrid oa status in the ScholarIQ index.
What is the DOI of Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis?
The DOI for Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis is on the source record.
What is the PMID of Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis?
The PMID for Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis is on the source record.
What is the OpenAlex record for Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis?
The OpenAlex for Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis is on the source record.